Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis: A 3 Cohorts Case Control Matched Study
This is a retrospective, exploratory, multi-center, translational, 3 cohorts case control matched study conducted in patients harboring a solid tumor with poor prognosis who presented a long-term (case) and standard (standard) survival. Patients with: * Cohort A: metastatic pancreatic ductal adenocarcinoma * Cohort B: glioblastoma IDHwt * Cohort C: extensive small cell lung cancer This research aims to integrate data generated from clinical records, imaging, multi-omics and bioinformatics approaches to discriminate case and control and then to identify new therapeutic targets. Analyses will be performed depending on the tumor samples available with at least 3 omics levels and according to scientific advances; genomic, epigenomic, proteomics, metabolomics, transcriptomic, microbiomic.
⁃ FOR SURVIVORS
• To be eligible the exceptional survivor patients must fulfill the following inclusion criteria:
‣ Adult patient (≥18 years old at diagnosis).
⁃ Three distinct cohorts, one of patients harbouring metastatic pancreatic ductal adenocarcinoma, glioblastoma IDHwt, extensive small cell lung cancer.
⁃ Long-term survival is defined as an exceptionally long survival ≥ 5 years from stage IV diagnosis for PDAC, extensive SCLC, and ≥ 3 years for GBM-IDHwt.
⁃ Availability of at least one block sample and associated clinical annotations with following characteristics:
• One block sample must be of sufficient quality and in sufficient quantity to perform multi-omic analyses, according to requirements specified in Lab manual
∙ Any treatment prior to sample acquisition must be reported - all treatments accepted (standard / targeted);
∙ Samples should be at least 5 years old for PDAC and SCLC and 3 years old for GBM
⁃ For CONTROL GROUPS :
• To be eligible the control patients must fulfill the following inclusion criteria:
‣ ≥18 years old at diagnosis.
⁃ Three distinct cohorts, one of patients suffering from metastatic pancreatic ductal adenocarcinoma, one for glioblastoma, one for extensive small cell lung cancer.
⁃ Paired to long-term survivors as mentioned in the methodology section
⁃ Death or median overall survival with a variation of 10% before of beyond as reported in pivotal clinical trials in the specific type disease
⁃ Availability of at least one tumor sample and associated clinical annotations with following characteristics:
• Sample must be of sufficient quality and in sufficient quantity to perform multi-omic analyses
∙ Any treatment prior to sample acquisition must be reported (treatment-naive samples should be preferred) - all treatments accepted (standard / targeted).